Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 05, 2007. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital transactions.
- Shares Repurchased: 2,300,000 ordinary shares.
- Repurchase Price: 1,299.2783 pence per share.
- Treasury Shares Held: 504,194,158 shares (representing 9.14% of total voting rights).
- Shares in Issue: 5,514,761,430 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,300,000 repurchased shares. Consequently, the number of shares held in Treasury has been updated to 504,194,158. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed beyond the standard regulatory conformity statement.
Investor Verification Checklist
- Verify the total number of shares in issue (5,514,761,430) for calculating ownership percentages under Disclosure Transparency Rules.
- Confirm the updated Treasury share count (504,194,158) and its impact on total voting rights (9.14%).
- Note that this filing does not contain financial results; refer to Form 20-F for comprehensive financial data.